Teva QVAR Inhaler Antitrust Settlement: Approved, Not Yet Paid

At a glance

Status

Approved, awaiting payment

Defendant

Teva Pharmaceuticals

Settlement fund

$35,000,000

Claim deadline

July 31, 2026

No-proof cash option

Yes — pro-rata (proof of purchase generally required for end-payor consumers; amount depends on the Plan of Allocation)

Estimated payout

pro-rata (proof of purchase generally required for end-payor consumers; amount depends on the Plan of Allocation)

Administrator

A.B. Data, Ltd.

Official site

www.qvarantitrustsettlement.com

Court

U.S. District Court, District of Massachusetts

Case number

23-cv-11131-NMG

Last verified September 9, 2026

Key dates

Milestone	Date	What it means
Claim deadline	July 31, 2026(passed)	Last day to file for a payment
Opt-out (exclusion) deadline	June 15, 2026(passed)	Last day to leave the settlement and keep the right to sue
Objection deadline	June 15, 2026(passed)	Last day to object to the terms
Final approval hearing	August 5, 2026(passed)	When the judge decides whether to approve the settlement
Expected payout	Not yet scheduled	Payments are not sent until after final approval and any appeals

Where to file

Teva QVAR Inhaler Antitrust Settlement is administered by A.B. Data, Ltd.. The only place to file is the official settlement website:

Verify on the official site

www.qvarantitrustsettlement.com

Filing is free. No legitimate settlement charges a fee to file a claim.

You cannot file on RecordingLaw.com. We are an independent publisher, not the settlement administrator, and we are not affiliated with any court, agency, or defendant.

The claim window for the Teva QVAR Inhaler Antitrust Settlement closed on July 31, 2026, and the court granted final approval on August 5, 2026. If you, or a health plan on your behalf, paid for a QVAR or QVAR RediHaler asthma inhaler sometime in the last decade, this settlement may have covered you. Here is what the underlying case is about, who the settlement covers, and what is left to happen.

What the lawsuit is about

This is not a data breach. No customer database or personal information is alleged to have been exposed in this case. It is a drug-pricing antitrust lawsuit: end-payor consumers and third-party payors, meaning people and health plans that ultimately paid for the medication, accused Teva Pharmaceuticals of using a patent and product-reformulation scheme to delay lower-cost generic versions of QVAR from reaching the market.

The claims cover purchases of QVAR or QVAR RediHaler inhalers made between January 1, 2015 and July 31, 2025 in the settlement's Class States. The theory is straightforward: if generic competition had entered sooner, prices would likely have been lower, so people and health plans that bought the brand-name inhaler during that window may have overpaid.

The case is pending in the U.S. District Court for the District of Massachusetts under case number 23-cv-11131-NMG. Teva Pharmaceuticals agreed to pay $35 million into a common settlement fund to resolve the claims.

Where this stands right now

As of September 9, 2026, this settlement has been finally approved and is waiting on distribution. The court set a schedule with several distinct deadlines, and it is easy to confuse them.

The exclusion deadline, the date by which someone could leave the class entirely and keep their own right to sue Teva separately, was June 15, 2026. That date has already passed. Opting out is different from objecting: objecting means staying in the class while telling the judge you think the deal's terms are unfair. The record reviewed for this page does not separately confirm an objection deadline; with final approval and judgment now entered, that window has closed along with the rest of the pre-hearing schedule.

The final approval hearing, sometimes called a fairness hearing, was held on August 5, 2026. The court entered an order granting final approval and judgment that same day, alongside an order awarding attorneys' fees. No payout date has been set yet. That is normal at this stage; funds in settlements like this one are typically not distributed until after any appeal period runs, so there is no confirmed date yet for when a payment would actually arrive.

The claim deadline, July 31, 2026, fell before the fairness hearing, and it has passed. If you did not file by that date, there is nothing left to submit through this settlement.

Who's actually in the class

The settlement covers end-payor consumers and third-party payors, not pharmacies or wholesalers. In plain terms, that means the people, or health plans covering people, who were the last stop in the payment chain for the drug, whether that payment was a cash purchase, a copay, or a premium a health plan later used to cover the cost. You may be eligible if you personally paid for QVAR or QVAR RediHaler out of pocket during the class period, or if a third-party payor, such as an employer health plan, made the purchase on your behalf.

Eligibility also depends on where the purchase happened. The class is limited to designated Class States, and the settlement record reviewed for this page does not list which states those are. Rather than guess, check your purchase against the official Notice and FAQ page, which spells out the exact state list and purchase window.

How much you can realistically expect

There is no fixed payout amount here. The $35 million fund will be divided pro rata among everyone who files a valid claim, and the actual dollar figure per person depends on how many people file, what the Plan of Allocation says, and what the court approves for attorneys' fees, expenses, and service awards. The settlement record does not state a minimum or typical payment, so do not go into this expecting a specific number.

Treat any number you might see elsewhere as a guess, not a promise. What you eventually receive, if anything, could be adjusted up or down from whatever an initial calculation suggests.

What proof you need to file

According to the settlement's own terms, end-payor consumers generally need some proof of purchase, such as a receipt, pharmacy printout, or insurance statement showing you paid for QVAR or QVAR RediHaler during the class period. A no-proof filing option also exists for people who no longer have that documentation, though the settlement's Plan of Allocation is what actually controls how claims with and without proof are weighted against each other. Check the official Notice and FAQ page for the specific document types accepted before you file.

How filing works

Filing happened only through the official claims process, administered by A.B. Data, Ltd. on behalf of the court; the link to it renders separately on this page. The deadline to file was July 31, 2026, and that window is now closed. The same official site is where the administrator posts distribution updates.

If the deadline has already passed for you, or your question isn't answered here

If you never filed by July 31, 2026, there is nothing further to submit for this claims process. The court granted final approval and entered judgment on August 5, 2026, so what remains is distribution, which the administrator posts on the official site. This matter did not involve a reported exposure of personal data, so the credit-freeze and identity-monitoring steps that make sense after an actual data breach do not apply here.

For other open, currently verified settlements, including actual data breach cases with their own separate claim windows, see RecordingLaw's data breach and privacy settlement tracker.